四川聚凯生物科技

Sichuan Jukai Biotechnology is a clinical-stage biopharmaceutical company headquartered in Chengdu, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on high-impact targets in oncology and metabolic diseases, utilizing its proprietary drug discovery platform to create differentiated candidates. Its lead program, JK-1109, is a selective CDK4/6 inhibitor currently in Phase 1 clinical trials for the treatment of advanced solid tumors. Jukai Biotech emphasizes independent research and development to address significant unmet clinical needs through rigorous scientific research and strategic clinical execution.